Author: TransCode Therapeutics, Inc.

Posted Date:

April 7, 2026

TransCode Therapeutics Enters into Agreements for up to $20 Million Flexible Financing, Extending Company’s Runway into Late 2027/Early 2028

TransCode Therapeutics, Inc.

April 7, 2026
TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer Patients

TransCode Therapeutics, Inc.

March 3, 2026
TransCode Therapeutics Announces Publication of Preclinical Testing of RIG-I Immunotherapeutic Candidate Supporting Further Development

TransCode Therapeutics, Inc.

February 23, 2026
TransCode Therapeutics and Quantum Leap Announce Submission of IND Amendment for Phase 2a Clinical Trial with TTX-MC138

TransCode Therapeutics, Inc.

February 7, 2026